Marpai receives $200,000 investment from CEO’s investment fund

TAMPA - Marpai, Inc. (OTCQX:MRAI), a third-party administration company for self-funded employer health plans, announced Monday it has secured a $200,000 private placement from HillCour Investment Fund, LLC, an entity controlled by the company’s Chief Executive Officer, Damien Lamendola. The company, currently valued at $28 million by market capitalization, has seen its stock surge over 155% in the past year, according to InvestingPro data.

The transaction involves the purchase of 147,058 shares of common stock at $1.36 per share, according to a company press release. This price represents a discount to the current trading price of $1.62. Marpai plans to use the proceeds for general corporate purposes, including accelerating deployment of advanced product offerings, expanding its technology platform, and increasing market penetration among self-funded employer groups. Based on InvestingPro’s Fair Value analysis, the stock appears to be trading near its fair value, with a Financial Health score rated as "FAIR."

"I continue to invest in Marpai because I believe in what we’re building," said Lamendola in the statement.

The offering was made under an exemption from registration requirements in Section 4(a)(2) of the Securities Act of 1933 and Regulation D, meaning the securities cannot be offered or sold in the United States except through an effective registration statement or applicable exemption.

This investment follows other fundraising efforts by the company, which has raised a total of $1.7 million in the third quarter of 2025.

Marpai operates in the third-party administration sector serving self-funded employer health plans. The company provides TPA and health plan services through its technology platform, competing in what it describes as a $150 billion TPA sector and $550 billion Pharmacy Benefit Management industry. Recent financial data shows annual revenue of $23.67 million, though the company faces challenges with negative EBITDA of $10.41 million. Get deeper insights into Marpai’s financial health and growth prospects with InvestingPro’s comprehensive research report, part of its coverage of over 1,400 US stocks.

The securities offered in the private placement are subject to restrictions under U.S. securities laws and applicable state securities laws.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.